Copy Link Print Information

U0126

467 Cited Publications
カスタマーレビュー

Based on 467 publication(s) in Google Scholar

U0126 is a potent, non-ATP competitive and selective MEK1 and MEK2 inhibitor, with IC50s of 72 nM and 58 nM, respectively. U0126 is an autophagy and mitophagy inhibitor.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

  • 純度: 98.57%
  • CAS 番号: 109511-58-2
  • 分子式: C18H16N6S2
  • 分子量:380.49
  • 保管条件:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 6 months , -20°C, 1 month
  • U0126 Chemical Structure
    U0126 構造式
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
  • Experimental Validation Results for U0126
CAS 番号: 109511-58-2
容量
価格（税別）
在庫状況
数量
Amount: USD 0.00
Please select quantity
or
or

* アイテムを追加する前、数量をご選択ください

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of U0126:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
最寄りの代理店をお探しください Your local distributor: Hycultec GmbHHycultec
  • 生物活性
  • 化学情報
  • 溶剤 & 溶解度
  • 純度とドキュメンテーション
  • 参考文献
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

MedChemExpress（MCE）の使用を引用している文献 U0126

More
Customer Validation & Images
IPBio/Physico-chemical AssayCell Proliferation/Viability AssayCell Imaging/StainingWBRT-PCRIF
  • Bio/Physico-chemical Assay
  • Bio/Physico-chemical Assay
  • Cell Imaging/Staining
  • IP
  • WB
  • Cell Proliferation/Viability Assay
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • RT-PCR
  • RT-PCR
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • IF
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB

MEK アイソフォーム固有の製品をすべて表示

More
Keywords
100 mg

お問い合わせ 在庫あり

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress ログイン
Register
Sign in to MedChemExpress
新規会員登録

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • U0126 Chemical Structure
    U0126 Chemical Structure
    1/16
  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2025 Oct;26(10):1673-1685. [Abstract]

    Customer Validation
     U0126 (20 μM, 30 min) and Mirdametinib enhanced LDH release in rPFO-treated HeLa cells.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2025 Oct;26(10):1673-1685. [Abstract]

    Customer Validation
     U0126 (20 μM, 30 min) and Mirdametinib enhanced rPFO-induced TGN remodeling and NLRP3 recruitment in HeLa NLRP3-GFP cells.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2025 Oct;26(10):1673-1685. [Abstract]

    Customer Validation
     U0126 (20 μM, 30 min) and Mirdametinib enhanced rPFO-induced TGN remodeling and NLRP3 recruitment in HeLa NLRP3-GFP cells.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2024 Nov;44(11):1350-1373. [Abstract]

    Customer Validation
     Ubiquitination assays in A549 cells showed that U0126 (2 μmol/L, 24 h) augments SET1A ubiquitination.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2024 Nov;44(11):1350-1373. [Abstract]

    Customer Validation
     U0126 (1-20 μmol/L, 24 h) significantly reduced FGL1 levels in KRAS-mutant lung cancer cells H358.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: NPJ Biofilms Microbiomes. 2024 Jan 20;10(1):5. [Abstract]

    Customer Validation
     Percentage cell proliferation of CT26 cells treated with MEK inhibitor U0126-EtOH (HY-12031; 25 µM), JNK inhibitor SP600125 (HY-12041; 25 µM), P38/MAPK inhibitor SB202190 (HY-10295; 20 µM), GSK3β inhibitor TWS119 (HY-10590; 20 µM), or AR-A014418 (HY-10512; 20 µM), and vehicle or Cori.ST1911. Cell OD was measured using the CCK8 method and normalised to cell proliferation of the control. Inhibitor treatment started 4 h before Cori.ST1911 treatment. Data are represented as mean ± SEM (n = 3 independent tests), analysed by one-way analysis of variance (ANOVA) with Bonferroni’s post-hoc test. n.s., no significance.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2023 Apr:210:115489. [Abstract]

    Customer Validation
     U0126 (20 uM; pretreat for 2 h) rescues the loss of UHRF1/DNMT1 expression and the increase of E-Cadherin expression that induced by Lenvatinib in Huh7 cells.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Mol Cell Endocrinol. 2023 May 1:566-567:111891. [Abstract]

    Customer Validation
     U0126 (10 uM; pre-treate for 1 h) attenuates IL-1-induced upregulation of COX-2 expression in KGN cells.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2019 Sep 1;79(17):4466-4479. [Abstract]

    Customer Validation
     Western blot and IHC analyses for p-ERK1/2 in lung tissues after vehicle or U0126 treatment.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Am J Physiol Renal Physiol. 2019 Apr 1;316(4):F660-F673. [Abstract]

    Customer Validation
     Western analysis of Vimentin, E-cadherin and Snail1 protein expression with or without the treatment of U0126.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Am J Physiol Renal Physiol. 2019 Apr 1;316(4):F660-F673. [Abstract]

    Customer Validation
     Western analysis of α-SMA, Collagen I and E-cadherin protein expression in the treatment of U0126 with different concentrations.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Acta Biochim Biophys Sin (Shanghai). 2019 Apr 1;51(4):365-374. [Abstract]

    Customer Validation
     MAPKs inhibitors suppress LPS-induced COX-2 expression and AKT1 phosphorylation. RAW264.7 cells are pretreated for 1 h with U0126, SB202190, SP600125 alone, or all the three inhibitors, respectively, and then exposed to 40 ng/ml LPS for 30 min or 12 h. The phosphorylated protein kinases and COX-2 expression are detected by western blot analysis using their corresponding antibodies.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Blood. 2018 Jul 12;132(2):210-222. [Abstract]

    Customer Validation
     Phosphorylation of p-ERK1/2 and p-Akt in MKs pretreated with 0.5 μM NVP-ADW742, 10 μM U0126 or 20 μM LY294002 followed by rhIGF-1 treatment for 15 minutes.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Biomaterials. 2018 Sep;178:95-108. [Abstract]

    Customer Validation
     U0126 effectively inhibits the phosphorylation of ERK, leading to the inhibition of IL-10 production.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2018 Jun 15;15(1):184. [Abstract]

    Customer Validation
     Representative immunoblots of total lysates from BV2 cells treated with MPP+or/and U0126 (10 μM), SP600125 (SP, 10 μM) and SB203580 (SB, 10 μM) using the antibodies against DICER.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2018 Aug 28:430:201-214. [Abstract]

    Customer Validation
     Inhibition of ERK suppresses N-cadherin expression. CD146WT or CD146KO MEFs are stimulated with or without TGF-β1 (10 ng/mL) for 24 h in the presence or absence of U0126 (2 μM). The expression and activation of ERK and the expression of E-cadherin and N-cadherin is assessed by immunoblotting.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2018 Oct 19;15(1):291. [Abstract]

    Customer Validation
     Blocking the three MAPK signaling pathways through specific inhibitors (U0126; SB202190; and SP600125) significantly decrease the infection-induced neuroinflammatory response via real-time PCR analysis.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2018 Oct 19;15(1):291. [Abstract]

    Customer Validation
     Blocking the three MAPK signaling pathways through specific inhibitors (U0126; SB202190; and SP600125) significantly decrease the infection-induced neuroinflammatory response via real-time PCR analysis.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Oct 3;9(10):1015. [Abstract]

    Customer Validation
     Representative western blot images are showing the LC3, and the phosphorylated and total protein expression of Akt and ERK1/2 after treatment with H2O2 in the presence and absence of MK2206 (5 μM) and U0126 (25 μM).

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Feb 15;9(3):269. [Abstract]

    Customer Validation
     WB is used to detect the effect of EGF treatment on the expression of YAP with the inhibitors of EGFR or its downsream members.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2018 Mar 15:42:152-163. [Abstract]

    Customer Validation
     Cells are pretreated with SP600125 (20 μM), SB203580 (20 μM) or U0126 (20 μM) in presence or absence of KLA, then incubated with LPS (1 μg/mL) for certain time. Cell lysates are subjected to western blot.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2018 Apr:100:417-425. [Abstract]

    Customer Validation
     HaCaT cells are pre-incubated with Compound C (CC) (10 μM) and U0126 (10 μM), pharmacological inhibitors of AMPKα, ERK, respectively, for 1 h before treatment with DA8 and DA14 (DAs).

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2018 Dec:108:1294-1302. [Abstract]

    Customer Validation
     The protein levels of IL-1β and TNF-α are sharply downregulated by the addition of inhibitors SB203580, SP600125, and U0126.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2018 Dec:108:1294-1302. [Abstract]

    Customer Validation
     The protein level of MMP-9 is downregulated by inhibitors SB203580, SP600125, and U0126.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2018 Dec:108:1294-1302. [Abstract]

    Customer Validation
     As for both 0 g and 3 g groups, the p-ERK1/2/ERK1/2 is notably reduced by inhibitors SB203580, SP600125, and U0126.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2018 Dec:108:1294-1302. [Abstract]

    Customer Validation
     As for both 0 g and 3 g groups, the p-p38&p38 is downregulated by inhibitors SB203580, SP600125, and U0126.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2018 Dec:108:1294-1302. [Abstract]

    Customer Validation
     As for both 0 g and 3 g groups, the p-JNK1&JNK1 is downregulated by inhibitors SB203580, SP600125, and U0126.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Front Immunol. 2018 Dec 7:9:2854. [Abstract]

    Customer Validation
     Neutrophils are pretreated with inhibitor of p38 MAPK (SB203580) and ERK1/2 (U0126), and the cells are then incubated with either SS2 ZY05719 or PMA for 3 h. Immunofluorescence is performed.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Reprod Biol Endocrinol. 2018 May 31;16(1):55. [Abstract]

    Customer Validation
     Western blot analysis of claudin 5, occludin and ZO-1 in TM4 cells, cells are treated with 100 nM Leptin or pre-treated with different inhibitors following a 100 nM Leptin treatment.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2018 Jun;17(6):7595-7602. [Abstract]

    Customer Validation
     Representative images show the expression levels of α SMA, calponin and osteopontin (OPN) protein.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: J Cell Biochem. 2019 Feb;120(2):1979-1989. [Abstract]

    Customer Validation
     Western blot shows the expression of p-ERK and MMP13 with the treatment of U0126 and CCL17.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Cell Physiol Biochem. 2018;50(4):1522-1534. [Abstract]

    Customer Validation
     Western analysis of effect of U0126 on Nell-1-induced changes in p-ERK, Runx2, OPG and Col-I protein expression in MC3T3-E1 preosteoblasts on Ti surfaces.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2017 May 1:393:22-32. [Abstract]

    Customer Validation
     Effects of p38 MAPK inhibitor (SB203580), ERK inhibitor (U0126), JNK inhibitor (SP600125), caspase inhibitor (Z-VAD-FMK) and NAC on SGC-7901 and MGC-803 treated with DOX/VCPA combination treatment. VCPA pretreatment strategy is the same as above. SB203580 (20 μM), U0126 (10 μM), SP600125 (20 μM), Z-VAD-FMK (10 μM) and NAC (5 mM) are treated 2 h before DOX (2 μg/mL) added into the culture, respectively. MAPK pathway protein levels are determined.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2017 Nov:112:49-59. [Abstract]

    Customer Validation
     Cells are pre-treated with ERK (U1026) and p38 (SB203580) inhibitors, followed by GL-V9 treatment for 24 h. Western blot is performed to analyze NAG-1 expression.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Cell Signal. 2017 Apr:32:48-58. [Abstract]

    Customer Validation
     Western blotting showing the hepaCAMexpression and the phosphorylation level of STAT3, ERK and AKT in cells treated with IL-6 (20 ng/mL) for 24 h with or without the pretreatment of two respective inhibitors, Stattic (10 μM) and U0126 (5 μM).

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Cell Cycle. 2017 Apr 3;16(7):714-722. [Abstract]

    Customer Validation
     Proliferation of OPCs by AST induced calcium signaling and phosphorylated ERK1/2. p-ERK levels decreased after Cx47 siRNA treatment and U0126-mediated ERK1/2 inhibition. The results of Western blotting show that U0126 causes a marked decrease in ERK1/2 phosphorylation

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Oxid Med Cell Longev. 2017:2017:6175841. [Abstract]

    Customer Validation
     Involvements of MAPK signaling pathway in CPS-induced apoptosis in ALI cultures of sheep bronchial epithelial cells. Cells are pretreated with U0126 (an ERK1/2 inhibitor, 10 μM) for 1 h, followed by exposure to CPS (100 ng/mL) or MO (MOI = 30) for 48 h. Cell lysates are subjected to Western blotting analysis using indicated antibodies.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 May 16;8(20):33807-33826. [Abstract]

    Customer Validation
     U0126 inhibits ERK1/2 activation in the kidney of hyperuricemic rats. Rat model of HN is established by feeding with adenine and potassium oxonate daily. In some rats, U0126 are simultaneously administrated intraperitoneally. After 28 days, the kidneys are taken for immunoblot analysis of p-ERK1/2, ERK1/2 or GAPDH.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Oxid Med Cell Longev. 2017:2017:7426458. [Abstract]

    Customer Validation
     Representative immunoblot analysis of p53, p16, p21, and retinoblastoma protein (Rb) in NP cells.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 May 30;8(47):82027-82036. [Abstract]

    Customer Validation
     U0126 and MEK162 block ERK activation (p-ERK1/2) in CZ415-treated U2OS cells.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: J Mol Cell Cardiol. 2015 Dec;89(Pt B):268-79. [Abstract]

    Customer Validation
     Dose response of MAPK and Akt inhibitors on cardiac fibroblast-derived exosomes (Exo)-induced activation of MAPKs and Akt. Neonatal rat cardiomyocytes are treated with or without Exo (50 μg/mL), U0126, SP600125, MK-2206, and SB023580 for 20 min and subjected to Western blot analysis. The results are from 4 separate experiments.

  • 1/16

    U0126 purchased from MedChemExpress. Usage Cited in: ACS Chem Neurosci. 2015 Jan 21;6(1):130-7. [Abstract]

    Customer Validation
     U0126 protects PC12 cells against H2O2-induced cell death. Western blot of ERK phosphorylation demonstrates that the MEK inhibitors U0126, GSK1120212 and Pimasertib are effective in blocking ERK phosphorylation under complete media, while U0124 results in slight ERK inhibition compared to DMSO control. Serum starvation results in lack of ERK phosphorylation in all conditions.

  • U0126